Top 100 – Scrip Asia 2022
The APAC biopharma industry is pursuing business as usual
Much of Asia has started gradually returning to some form of post-pandemic normalcy and COVID-19 has become an engrained feature of everyday life. Close to three years after the Wuhan outbreak, perhaps the single biggest difference has been a strategic shift in many countries to various attempts to “live with the virus.” Besides the ongoing pandemic response and impact, the APAC biopharma industry is pursuing business as usual.
China continues to emerge as a key innovator
While there have been no landmark M&A deals over the past year, China continues to emerge as a hotbed of rising innovation, with mRNA becoming the trending new area alongside the increasingly crowded immuno-oncology space.
Alongside the country’s independent push into global markets – albeit with some major road bumps in the US – its R&D capabilities are being increasingly tapped by western big pharma.
India, South Korea and Japan look forward
India continues to progress its vaccines sector across multiple fronts, while its generic firms face rising pricing pressures in the US. South Korea moves steadily down the path to more innovation and globalization, and while it has long been a mature market, Japan remains a key part of the regional picture, making moves to support homegrown vaccines and drugs for future pandemics.
Download sample report
Through a financial performance ranking of the region’s top companies, along with penetrating insights and deep analysis of the top trends, events, and developments for APAC in 2022, Scrip Asia 100 provides critical insights into the activities shaping Asia’s pharma landscape as we know it.
Download your report today
Get full access with a free trial
Scrip subscribers enjoy full access to essential reports that fuel their decision making, including the Scrip Asia 100. Register today for your free, 7-day trial of Scrip and experience the full power of the leading provider of critical news, data, and analysis for commercial biopharma leaders worldwide.
Start your free trialAbout Scrip
Gain a broader perspective, identify disruptive events, and spot opportunities others might miss, with Scrip. Discover how you can leverage the expertise of Scrip’s worldwide team of experienced industry journalists and analysts who bring you latest news and insights on everything from competitor activity to licensing to clinical trials and more.
Register for your free 7-day trial →